2Q EARNINGS: J&J flaunts pharma future; investors wary
This article was originally published in Scrip
Executive Summary
Investors obsessed over the spike in Johnson & Johnson's Olysio (simeprevir) sales – from $354m in the first quarter to $831m in the second – and an expected slump later this year due to new competition in hepatitis C, despite the company's message on 15 July about its pharmaceutical future.